Navigation Links
De nouvelles données mettent en évidence le fardeau considérable que représente la nycturie
Date:3/17/2013

MILAN, March 17, 2013 /PRNewswire/ --

Affection chronique associée à des troubles du sommeil et à une perte notable

de productivité et d'activité non liée au travail

De nouvelles données présentées aujourd'hui au congrès de l'Association européenne d'urologie (EAU) montrent que la nycturie (le besoin d'uriner une ou plusieurs fois la nuit) est associée à une réduction importante de la productivité au travail et des activités de loisirs, de manière semblable à d'autres troubles chroniques comme l'asthme, la BPCO (bronchopathie obstructive chronique) et le RGO (reflux gastro-oesophagien).[1] Il a été démontré que la nycturie réduisait de près de 25 % la productivité au travail de la population active.[1]

Par ailleurs, d'autres résultats d'étude montrent que chez ceux qui en souffrent, les troubles du sommeil représentent le symptôme le plus difficile à supporter. Environ un tiers des personnes souffrant de nycturie sont incapables de retrouver le sommeil et deviennent insomniaques.[2]

La fragmentation du sommeil est une conséquence grave de la nycturie et peut affecter négativement les performances dans la journée.  Une analyse des données obtenues à partir de deux études cliniques randomisées et contrôlées (n=646) sur trois mois, a été effectuée dans le cadre d'une évaluation économique visant à comparer les effets de la nycturie sur la productivité et l'activité par rapport à d'autres maladies chroniques.  La productivité au travail a été évaluée grâce au questionnaire sur la dégradation de l'activité et de la productivité au travail.[3]

'/>"/>
SOURCE Ferring Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Elsevier Launches Evidence-Based, Collaborative Order Sets Solution
2. More evidence needed for scale up of mobile device technology in health
3. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
4. First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
5. endpoint Adopts New Technology To Boast Most Robust IVR Validation Objective Evidence and Decrease IVR Build Timelines
6. New Epidemiological Data Provide Additional Safety Evidence for Lantus®
7. More evidence for longevity pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... KY and Manhattan, KS (PRWEB) , ... June ... ... has acquired US PATENT 7736892 B2. Under the terms of the agreement, MediVet ... Umbilical Cord Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as ...
(Date:6/29/2015)... June 29, 2015  AACC, a global scientific ... through laboratory medicine, is pleased to announce that ... Chemistry , has increased to 7.9 in the ... places Clinical Chemistry in the top ... significant influence of the research it publishes on ...
(Date:6/29/2015)... June 29, 2015 According to a ... XNA), by Application (Diagnostics, Therapeutics, R&D), by Technology (SELEX, Other ... Companies, CRO) - Global Forecast to 2020", published by MarketsandMarkets, ... by 2020 from $107.56 Million in 2015, at a CAGR ... ables and 67 F igures spread through ...
(Date:6/29/2015)... , June 29, 2015   For the seventh year ... to assess their overall digital maturity called the ... these companies are not maturing fast enough. While it,s ... in numerous ways overall and customers are increasingly "digital ... of digital customer engagement.  ...
Breaking Biology Technology:MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Aptamers Market Worth $244.93 Million by 2020 2Aptamers Market Worth $244.93 Million by 2020 3Aptamers Market Worth $244.93 Million by 2020 4Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4
... Key Secondary Endpoints,NEW YORK, March 10 Intra-Cellular Therapies, ... Phase II trial in patients with Sleep Maintenance Insomnia ... increased slow wave sleep and decreased the duration of ... meeting the prespecified primary and key secondary endpoints of ...
... March 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... positive clinical study results for its Bio-Seal(TM) Lung ... Interventional Radiologists Annual Scientific Meeting in San Diego, ... of Bio-Seal in patients undergoing lung biopsy procedures ...
... 9 Former Presidential candidate Gary Bauer on Monday called ... embryonic stem cell research "evidence that ideology is the goal ... a tragedy, as lives will be lost and not saved ... Values made the following statement: "It,s tragic that Barack Obama ...
Cached Biology Technology:Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7Angiotech announces positive results from Bio-Seal(TM) clinical study 2Angiotech announces positive results from Bio-Seal(TM) clinical study 3Angiotech announces positive results from Bio-Seal(TM) clinical study 4Angiotech announces positive results from Bio-Seal(TM) clinical study 5
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical ... use solutions, headquartered in Springville, Utah , ... California corporation with locations in Santa ... Rica ). This acquisition will incorporate MedConx,s ... ATL Technology,s existing facility in Costa Rica ...
(Date:6/24/2015)... 24, 2015 This report provides market analysis ... six years. It contains an analysis of the drivers, ... their impact from the short, medium, and long term ... industry, market, and technology trends that currently, prevail in ... concerned authorities to efficiently manage the increasing marine traffic ...
(Date:6/23/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/vq2k2f/bodyworn ... "Body-Worn Temperature Sensors Market - Global Industry Analysis, ... 2020" report to their offering. ... body-worn temperature sensors market. The global body-worn temperature ... of types, care setting, patient demographic, applications and ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... A team from the National Institute of Standards ... Guard on a coordinated effort to train emergency first ... securing reliable samples of suspected biothreats. The project, dubbed ... first responders at the state, local and federal levels ...
... in the journal Annals of Botany , Professor Douglas ... in the ground could harvest more carbon from the air, ... levels. In principle, any crops could be treated in ... for the environment. Although the amount of carbon presently ...
... Nobel Prize for nerve growth factor was awarded more than ... use growth factor clinically. University of Pittsburgh Professor Yadong ... factor to regrow blood vessels. His research, which could be ... death in the Western world, is published this week in ...
Cached Biology News:Operation Vigilant Sample: First responder training for suspicious powders 2Crop breeding could 'slash CO2 levels' 2Regrowing blood vessels with a potent molecule 2Regrowing blood vessels with a potent molecule 3Regrowing blood vessels with a potent molecule 4
...
... feature a dual strength adhesive system which facilitates ... The adhesives on either side of the frame ... to the glass has an easy release adhesive ... forms a stronger bond. This means that when ...
... Cultures (ECACC) has been offering training courses ... institutes for over seven years. We offer ... candidates to cell culture and a Level ... areas such as planning and management of ...
... cover slips for in situ hybridization,in ... on glass slides., Constant probe ... not adsorb probes. , Ready-to-use-Hybri-slips do ... , Avoid RNA degradation-Hybri-slips are supplied ...
Biology Products: